Skip to main content
Top
Published in: BMC Nephrology 1/2021

Open Access 01-12-2021 | Kidney Transplantation | Research article

Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation

Authors: Sami Alasfar, Isaac E. Hall, Sherry G. Mansour, Yaqi Jia, Heather R. Thiessen-Philbrook, Francis L. Weng, Pooja Singh, Bernd Schröppel, Thangamani Muthukumar, Sumit Mohan, Rubab F. Malik, Meera N. Harhay, Mona D. Doshi, Enver Akalin, Jonathan S. Bromberg, Daniel C. Brennan, Peter P. Reese, Chirag R. Parikh

Published in: BMC Nephrology | Issue 1/2021

Login to get access

Abstract

Background

Post-Transplant erythrocytosis (PTE) has not been studied in large recent cohorts. In this study, we evaluated the incidence, risk factors, and outcome of PTE with current transplant practices using the present World Health Organization criteria to define erythrocytosis. We also tested the hypothesis that the risk of PTE is greater with higher-quality kidneys.

Methods

We utilized the Deceased Donor Study which is an ongoing, multicenter, observational study of deceased donors and their kidney recipients that were transplanted between 2010 and 2013 across 13 centers. Eryrthocytosis is defined by hemoglobin> 16.5 g/dL in men and> 16 g/dL in women. Kidney quality is measured by Kidney Donor Profile Index (KDPI).

Results

Of the 1123 recipients qualified to be in this study, PTE was observed at a median of 18 months in 75 (6.6%) recipients. Compared to recipients without PTE, those with PTE were younger [mean 48±11 vs 54±13 years, p < 0.001], more likely to have polycystic kidney disease [17% vs 6%, p < 0.001], have received kidneys from younger donors [36 ±13 vs 41±15 years], and be on RAAS inhibitors [35% vs 22%, p < 0.001]. Recipients with PTE were less likely to have received kidneys from donors with hypertension [16% vs 32%, p = 0.004], diabetes [1% vs 11%, p = 0.008], and cerebrovascular event (24% vs 36%, p = 0.036). Higher KDPI was associated with decreased PTE risk [HR 0.98 (95% CI: 0.97–0.99)]. Over 60 months of follow-up, only 17 (36%) recipients had sustained PTE. There was no association between PTE and graft failure or mortality,

Conclusions

The incidence of PTE was low in our study and PTE resolved in majority of patients. Lower KDPI increases risk of PTE. The underutilization of RAAS inhibitors in PTE patients raises the possibility of under-recognition of this phenomenon and should be explored in future studies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wickre CG, Norman DJ, Bennison A, et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int. 1983;23(5):731–7.PubMedCrossRef Wickre CG, Norman DJ, Bennison A, et al. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int. 1983;23(5):731–7.PubMedCrossRef
2.
go back to reference Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis. 1994;24(1):1–11.PubMedCrossRef Gaston RS, Julian BA, Curtis JJ. Posttransplant erythrocytosis: an enigma revisited. Am J Kidney Dis. 1994;24(1):1–11.PubMedCrossRef
3.
go back to reference Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis. Kidney Int. 2003;63(4):1187–94.PubMedCrossRef Vlahakos DV, Marathias KP, Agroyannis B, et al. Posttransplant erythrocytosis. Kidney Int. 2003;63(4):1187–94.PubMedCrossRef
4.
go back to reference Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001–6.PubMedCrossRef Augustine JJ, Knauss TC, Schulak JA, et al. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant. 2004;4(12):2001–6.PubMedCrossRef
5.
go back to reference Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transpl. 2009;23(6):800–6.CrossRef Kiberd BA. Post-transplant erythrocytosis: a disappearing phenomenon? Clin Transpl. 2009;23(6):800–6.CrossRef
6.
go back to reference Einollahi B, Lessan-Pezeshki M, Nafar M, et al. Erythrocytosis after renal transplantation: review of 101 cases. Transplant Proc. 2005;37(7):3101–2.PubMedCrossRef Einollahi B, Lessan-Pezeshki M, Nafar M, et al. Erythrocytosis after renal transplantation: review of 101 cases. Transplant Proc. 2005;37(7):3101–2.PubMedCrossRef
7.
go back to reference Kessler M, Hestin D, Mayeux D, et al. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol. 1996;45(2):83–9.PubMed Kessler M, Hestin D, Mayeux D, et al. Factors predisposing to post-renal transplant erythrocytosis. A prospective matched-pair control study. Clin Nephrol. 1996;45(2):83–9.PubMed
8.
go back to reference Tatman AJ, Tucker B, Amess JA, et al. Erythraemia in renal transplant recipients treated with cyclosporin. Lancet. 1988;1(8597):1279.PubMedCrossRef Tatman AJ, Tucker B, Amess JA, et al. Erythraemia in renal transplant recipients treated with cyclosporin. Lancet. 1988;1(8597):1279.PubMedCrossRef
9.
go back to reference Qunibi WY, Barri Y, Devol E, et al. Factors predictive of post-transplant erythrocytosis. Kidney Int. 1991;40(6):1153–9.PubMedCrossRef Qunibi WY, Barri Y, Devol E, et al. Factors predictive of post-transplant erythrocytosis. Kidney Int. 1991;40(6):1153–9.PubMedCrossRef
10.
go back to reference Danovitch GM, Jamgotchian NJ, Eggena PH, et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation. 1995;60(2):132–7.PubMedCrossRef Danovitch GM, Jamgotchian NJ, Eggena PH, et al. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism. Transplantation. 1995;60(2):132–7.PubMedCrossRef
11.
go back to reference Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol. 1988;29(3):119–23.PubMed Pollak R, Maddux MS, Cohan J, et al. Erythrocythemia following renal transplantation: influence of diuretic therapy. Clin Nephrol. 1988;29(3):119–23.PubMed
12.
go back to reference Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors of erythrocytosis post renal transplantation. Saudi J Kidney Dis Transpl. 2008;19(4):559–63.PubMed Razeghi E, Kaboli A, Pezeshki ML, et al. Risk factors of erythrocytosis post renal transplantation. Saudi J Kidney Dis Transpl. 2008;19(4):559–63.PubMed
13.
go back to reference Guerra G, Indahyung R, Bucci CM, et al. Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation. Am J Transplant. 2010;10(4):938–42.PubMedCrossRef Guerra G, Indahyung R, Bucci CM, et al. Elevated incidence of posttransplant erythrocytosis after simultaneous pancreas kidney transplantation. Am J Transplant. 2010;10(4):938–42.PubMedCrossRef
14.
go back to reference Special Issue. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(s3):S1–S155. Special Issue. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9(s3):S1–S155.
15.
go back to reference Barbui T, Thiele J, Gisslinger H, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016;30(6):453–9.PubMedCrossRef Barbui T, Thiele J, Gisslinger H, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. Blood Rev. 2016;30(6):453–9.PubMedCrossRef
16.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. (Eds.) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC; 2008.
17.
go back to reference Potluri VS, Parikh CR, Hall IE, et al. Validating Early Post-Transplant Outcomes Reported for Recipients of Deceased Donor Kidney Transplants. Clin J Am Soc Nephrol. 2016;11(2):324–31.PubMedCrossRef Potluri VS, Parikh CR, Hall IE, et al. Validating Early Post-Transplant Outcomes Reported for Recipients of Deceased Donor Kidney Transplants. Clin J Am Soc Nephrol. 2016;11(2):324–31.PubMedCrossRef
18.
go back to reference Hall IE, Schroppel B, Doshi MD, et al. Associations of deceased donor kidney injury with kidney discard and function after transplantation. Am J Transplant. 2015;15(6):1623–31.PubMedPubMedCentralCrossRef Hall IE, Schroppel B, Doshi MD, et al. Associations of deceased donor kidney injury with kidney discard and function after transplantation. Am J Transplant. 2015;15(6):1623–31.PubMedPubMedCentralCrossRef
19.
go back to reference Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated with kidney allograft failure. Kidney Int. 2019;95(1):199–209.PubMedCrossRef Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated with kidney allograft failure. Kidney Int. 2019;95(1):199–209.PubMedCrossRef
20.
go back to reference Reese PP, Hall IE, Weng FL, et al. Associations between Deceased-Donor Urine Injury Biomarkers and Kidney Transplant Outcomes. J Am Soc Nephrol. 2016;27(5):1534–43.PubMedCrossRef Reese PP, Hall IE, Weng FL, et al. Associations between Deceased-Donor Urine Injury Biomarkers and Kidney Transplant Outcomes. J Am Soc Nephrol. 2016;27(5):1534–43.PubMedCrossRef
21.
go back to reference Dickinson DM, Bryant PC, Williams MC, et al. Transplant data: sources, collection, and caveats. Am J Transplant. 2004;4(Suppl 9):13–26.PubMedCrossRef Dickinson DM, Bryant PC, Williams MC, et al. Transplant data: sources, collection, and caveats. Am J Transplant. 2004;4(Suppl 9):13–26.PubMedCrossRef
22.
go back to reference Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231–6.PubMedCrossRef Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009;88(2):231–6.PubMedCrossRef
24.
go back to reference Lin DY, Wei LJ, Ying Z. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika. 1993;80(3):557–72.CrossRef Lin DY, Wei LJ, Ying Z. Checking the Cox Model with Cumulative Sums of Martingale-Based Residuals. Biometrika. 1993;80(3):557–72.CrossRef
25.
go back to reference Dagher FJ, Ramos E, Erslev A, et al. Erythrocytosis after renal allotransplantation: treatment by removal of the native kidneys. South Med J. 1980;73(7):940–2.PubMedCrossRef Dagher FJ, Ramos E, Erslev A, et al. Erythrocytosis after renal allotransplantation: treatment by removal of the native kidneys. South Med J. 1980;73(7):940–2.PubMedCrossRef
26.
go back to reference Bacon BR, Rothman SA, Ricanati ES, et al. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med. 1980;140(9):1206–11.PubMedCrossRef Bacon BR, Rothman SA, Ricanati ES, et al. Renal artery stenosis with erythrocytosis after renal transplantation. Arch Intern Med. 1980;140(9):1206–11.PubMedCrossRef
27.
go back to reference Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol. 1998;9(6):1104–8.PubMed Julian BA, Brantley RR Jr, Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol. 1998;9(6):1104–8.PubMed
28.
go back to reference Ducloux D, Fournier V, Bresson-Vautrin C, et al. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int. 1998;11(4):312–5.PubMedCrossRef Ducloux D, Fournier V, Bresson-Vautrin C, et al. Long-term follow-up of renal transplant recipients treated with losartan for post-transplant erythrosis. Transpl Int. 1998;11(4):312–5.PubMedCrossRef
29.
go back to reference Mazzali M, Filho GA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation. 1998;65(11):1461–4.PubMedCrossRef Mazzali M, Filho GA. Use of aminophylline and enalapril in posttransplant polycythemia. Transplantation. 1998;65(11):1461–4.PubMedCrossRef
30.
go back to reference MacGregor MS, Rowe PA, Watson MA, et al. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Nephron. 1996;74(3):517–21.PubMedCrossRef MacGregor MS, Rowe PA, Watson MA, et al. Treatment of postrenal transplant erythrocytosis. Long-term efficacy and safety of angiotensin-converting enzyme inhibitors. Nephron. 1996;74(3):517–21.PubMedCrossRef
31.
go back to reference Montanaro D, Groupuzzo M, Boscutti G, et al. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clin Nephrol. 2000;53(4):suppl 47–51. Montanaro D, Groupuzzo M, Boscutti G, et al. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms. Clin Nephrol. 2000;53(4):suppl 47–51.
32.
go back to reference Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis. 1995;26(3):495–500.PubMedCrossRef Perazella M, McPhedran P, Kliger A, et al. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. Am J Kidney Dis. 1995;26(3):495–500.PubMedCrossRef
33.
go back to reference Hestin D, Legrand E. Mertes M et al: [Polycythemia after kidney transplantation]. Presse Med. 1992;21(41):1973–4.PubMed Hestin D, Legrand E. Mertes M et al: [Polycythemia after kidney transplantation]. Presse Med. 1992;21(41):1973–4.PubMed
34.
go back to reference Frei D, Guttmann RD, Gorman P. A matched-pair control study of postrenal transplant polycythemia. Am J Kidney Dis. 1982;2(1):36–42.PubMedCrossRef Frei D, Guttmann RD, Gorman P. A matched-pair control study of postrenal transplant polycythemia. Am J Kidney Dis. 1982;2(1):36–42.PubMedCrossRef
35.
go back to reference Barenbrock M, Spieker C, Rahn KH, et al. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol. 1993;40(4):241–3.PubMed Barenbrock M, Spieker C, Rahn KH, et al. Therapeutic efficiency of phlebotomy in posttransplant hypertension associated with erythrocytosis. Clin Nephrol. 1993;40(4):241–3.PubMed
36.
go back to reference Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990;323(2):86–90.PubMedCrossRef Bakris GL, Sauter ER, Hussey JL, et al. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med. 1990;323(2):86–90.PubMedCrossRef
Metadata
Title
Contemporary incidence and risk factors of post transplant Erythrocytosis in deceased donor kidney transplantation
Authors
Sami Alasfar
Isaac E. Hall
Sherry G. Mansour
Yaqi Jia
Heather R. Thiessen-Philbrook
Francis L. Weng
Pooja Singh
Bernd Schröppel
Thangamani Muthukumar
Sumit Mohan
Rubab F. Malik
Meera N. Harhay
Mona D. Doshi
Enver Akalin
Jonathan S. Bromberg
Daniel C. Brennan
Peter P. Reese
Chirag R. Parikh
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2021
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-021-02231-2

Other articles of this Issue 1/2021

BMC Nephrology 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.